Stock Track | Xenon Pharmaceuticals Surges 7.01% Pre-market on Multiple Analyst Buy Ratings

Stock Track

Aug 12, 2025

Xenon Pharmaceuticals (XENE) stock soared 7.01% in pre-market trading on Tuesday, following a series of positive analyst ratings and price targets. The biotechnology company, known for its innovative approach to developing treatments for neurological disorders, has caught the attention of several major financial institutions.

William Blair analyst Myles Minter reiterated a Buy rating on Xenon, citing the company's promising clinical pipeline and strategic progress. RBC Capital's Brian Abrahams also maintained a Buy rating with a price target of $55.00, while Wells Fargo analyst Mohit Bansal set a $47.00 price target, both expressing confidence in the company's potential.

Despite Deutsche Bank slightly lowering its target price from $60 to $57, the overall sentiment remains bullish. The multiple Buy ratings from reputable analysts appear to have boosted investor confidence, driving the significant pre-market surge. As Xenon Pharmaceuticals continues to advance its drug candidates through clinical trials, market participants seem optimistic about the company's future prospects in the competitive pharmaceutical landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1148216814"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148216814\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148216814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148216814","market":"nz","top_or_hot":-1,"title":"Stock Track | Xenon Pharmaceuticals Surges 7.01% Pre-market on Multiple Analyst Buy Ratings","media":"Stock Track","content":"<p>Xenon Pharmaceuticals (XENE) stock soared 7.01% in pre-market trading on Tuesday, following a series of positive analyst ratings and price targets. The biotechnology company, known for its innovative approach to developing treatments for neurological disorders, has caught the attention of several major financial institutions.</p>\n\n<p>William Blair analyst Myles Minter reiterated a Buy rating on Xenon, citing the company's promising clinical pipeline and strategic progress. RBC Capital's Brian Abrahams also maintained a Buy rating with a price target of $55.00, while Wells Fargo analyst Mohit Bansal set a $47.00 price target, both expressing confidence in the company's potential.</p>\n\n<p>Despite Deutsche Bank slightly lowering its target price from $60 to $57, the overall sentiment remains bullish. The multiple Buy ratings from reputable analysts appear to have boosted investor confidence, driving the significant pre-market surge. As Xenon Pharmaceuticals continues to advance its drug candidates through clinical trials, market participants seem optimistic about the company's future prospects in the competitive pharmaceutical landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Xenon Pharmaceuticals Surges 7.01% Pre-market on Multiple Analyst Buy Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Xenon Pharmaceuticals Surges 7.01% Pre-market on Multiple Analyst Buy Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-12 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xenon Pharmaceuticals (XENE) stock soared 7.01% in pre-market trading on Tuesday, following a series of positive analyst ratings and price targets. The biotechnology company, known for its innovative approach to developing treatments for neurological disorders, has caught the attention of several major financial institutions.</p>\n\n<p>William Blair analyst Myles Minter reiterated a Buy rating on Xenon, citing the company's promising clinical pipeline and strategic progress. RBC Capital's Brian Abrahams also maintained a Buy rating with a price target of $55.00, while Wells Fargo analyst Mohit Bansal set a $47.00 price target, both expressing confidence in the company's potential.</p>\n\n<p>Despite Deutsche Bank slightly lowering its target price from $60 to $57, the overall sentiment remains bullish. The multiple Buy ratings from reputable analysts appear to have boosted investor confidence, driving the significant pre-market surge. As Xenon Pharmaceuticals continues to advance its drug candidates through clinical trials, market participants seem optimistic about the company's future prospects in the competitive pharmaceutical landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XENE","symbol_name":"Xenon制药","start_time":0,"source_url":"","article_id":"1148216814","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148216814","pubTimestamp":1754998000,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Xenon Pharmaceuticals (XENE) stock soared 7.01% in pre-market trading on Tuesday, following a series of positive analyst ratings and price targets. The biotechnology company, known for its innovative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XENE":"Xenon制药"},"translate_title":"个股追踪|多位分析师给予买入评级Xenon Pharmaceuticals盘前大涨7.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XENE":1},"content_text":"Xenon Pharmaceuticals (XENE) stock soared 7.01% in pre-market trading on Tuesday, following a series of positive analyst ratings and price targets. The biotechnology company, known for its innovative approach to developing treatments for neurological disorders, has caught the attention of several major financial institutions.\nWilliam Blair analyst Myles Minter reiterated a Buy rating on Xenon, citing the company's promising clinical pipeline and strategic progress. RBC Capital's Brian Abrahams also maintained a Buy rating with a price target of $55.00, while Wells Fargo analyst Mohit Bansal set a $47.00 price target, both expressing confidence in the company's potential.\nDespite Deutsche Bank slightly lowering its target price from $60 to $57, the overall sentiment remains bullish. The multiple Buy ratings from reputable analysts appear to have boosted investor confidence, driving the significant pre-market surge. As Xenon Pharmaceuticals continues to advance its drug candidates through clinical trials, market participants seem optimistic about the company's future prospects in the competitive pharmaceutical landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}